Imexpharm Corporation (HOSE:IMP)
51,100
-100 (-0.20%)
At close: Jun 26, 2025
Imexpharm Cash Flow Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 333,403 | 320,862 | 299,556 | 223,540 | 189,095 | 209,697 | Upgrade
|
Depreciation & Amortization | 103,874 | 104,235 | 82,642 | 60,386 | 60,412 | 53,361 | Upgrade
|
Other Amortization | 1,402 | 1,402 | - | - | - | - | Upgrade
|
Loss (Gain) From Sale of Assets | -11,880 | -8,759 | -22,410 | -19,861 | -18,628 | -9,977 | Upgrade
|
Other Operating Activities | -156,660 | -128,550 | -32,171 | -6,126 | -45,582 | -1,784 | Upgrade
|
Change in Accounts Receivable | -332,901 | -83,307 | -30,534 | 20,136 | 115,759 | -60,836 | Upgrade
|
Change in Inventory | 44,871 | -6,181 | -260,749 | 52,398 | -66,129 | -75,247 | Upgrade
|
Change in Accounts Payable | 150,478 | 20,278 | 25,481 | 39,580 | -2,831 | -49,526 | Upgrade
|
Change in Other Net Operating Assets | -30,039 | -3,711 | -101,351 | 7,018 | -2,159 | 7,465 | Upgrade
|
Operating Cash Flow | 102,548 | 216,268 | -39,535 | 378,603 | 234,881 | 73,153 | Upgrade
|
Operating Cash Flow Growth | - | - | - | 61.19% | 221.08% | 9.86% | Upgrade
|
Capital Expenditures | -103,967 | -96,771 | -63,530 | -99,353 | -52,857 | -89,685 | Upgrade
|
Sale of Property, Plant & Equipment | 1,040 | 4,832 | 2,533 | 582.73 | 8,655 | 4,889 | Upgrade
|
Investment in Securities | -42,935 | -42,935 | 118,300 | -118,327 | -244,945 | -105,940 | Upgrade
|
Other Investing Activities | 8,510 | 7,675 | 21,817 | 17,794 | 10,106 | 6,585 | Upgrade
|
Investing Cash Flow | -108,683 | -127,199 | 79,121 | -199,304 | -83,142 | -136,476 | Upgrade
|
Short-Term Debt Issued | - | 387,994 | 229,739 | 59,803 | - | 408,998 | Upgrade
|
Long-Term Debt Issued | - | - | - | - | 324,785 | - | Upgrade
|
Total Debt Issued | 617,047 | 387,994 | 229,739 | 59,803 | 324,785 | 408,998 | Upgrade
|
Short-Term Debt Repaid | - | -351,294 | -275,298 | - | - | - | Upgrade
|
Long-Term Debt Repaid | - | - | - | -231,514 | -190,282 | -315,649 | Upgrade
|
Total Debt Repaid | -346,649 | -351,294 | -275,298 | -231,514 | -190,282 | -315,649 | Upgrade
|
Net Debt Issued (Repaid) | 270,398 | 36,700 | -45,558 | -171,711 | 134,503 | 93,348 | Upgrade
|
Issuance of Common Stock | - | - | - | - | - | 29,632 | Upgrade
|
Common Dividends Paid | -70,005 | -70,005 | -66,672 | -100,007 | -100,007 | -49,387 | Upgrade
|
Financing Cash Flow | 200,393 | -33,305 | -112,230 | -271,718 | 34,496 | 73,592 | Upgrade
|
Foreign Exchange Rate Adjustments | 19.18 | 19.18 | -0.59 | -9.19 | -230.63 | -36.79 | Upgrade
|
Net Cash Flow | 194,277 | 55,783 | -72,645 | -92,428 | 186,004 | 10,233 | Upgrade
|
Free Cash Flow | -1,419 | 119,497 | -103,064 | 279,250 | 182,024 | -16,531 | Upgrade
|
Free Cash Flow Growth | - | - | - | 53.41% | - | - | Upgrade
|
Free Cash Flow Margin | -0.06% | 5.42% | -5.17% | 16.99% | 14.37% | -1.21% | Upgrade
|
Free Cash Flow Per Share | -9.21 | 775.91 | -669.21 | 1813.19 | 1181.89 | -110.47 | Upgrade
|
Cash Interest Paid | 4,259 | 3,491 | 6,700 | 4,475 | 4,227 | 5,310 | Upgrade
|
Cash Income Tax Paid | 83,433 | 70,806 | 83,992 | 59,624 | 45,310 | 40,856 | Upgrade
|
Levered Free Cash Flow | 24,271 | 145,454 | -69,934 | 274,201 | 211,391 | -18,044 | Upgrade
|
Unlevered Free Cash Flow | 27,595 | 147,635 | -66,162 | 276,573 | 214,826 | -14,664 | Upgrade
|
Change in Net Working Capital | 244,087 | 120,705 | 323,429 | -130,228 | -60,976 | 142,437 | Upgrade
|
Updated Jan 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.